靶向单核细胞内在的增强子重编程可提高肝细胞癌的免疫治疗疗效
该研究在纤维化/肝硬化微环境的肝细胞癌模型中,发现单核细胞样髓源性抑制细胞(M-MDSC)积累与肿瘤浸润淋巴细胞减少及肿瘤生长增强相关,其机制涉及活化的肝星状细胞诱导单核细胞p38 MAPK信号触发的增强子重编程。BET溴结构域抑制剂i-BET762联合抗PD-L1可协同增强肿瘤浸润淋巴细胞、根除肿瘤并延长生存期。
要点
- 纤维化肝内M-MDSC而非多形核MDSC的积累与肿瘤浸润淋巴细胞减少及肿瘤生长增强显著相关。
- 人肝细胞癌肿瘤周围纤维化肝组织富含M-MDSC,其替代标志物CD33与侵袭性表型和较差生存率显著相关。
- i-BET762联合抗PD-L1协同增强肿瘤浸润淋巴细胞并延长纤维化肝细胞癌小鼠生存期。
核心结论
- 纤维化微环境中的非肿瘤内在特性可被利用以恢复免疫监视,提供可转化的联合免疫治疗策略。
研究设计与样本
- 研究采用两种原位肝细胞癌小鼠模型(四氯化碳或高脂高碳水化合物饮食诱导纤维化肝背景),通过流式细胞术评估MDSC功能意义,并用临床标本验证。
- 机制研究在人肝星状细胞-外周血单核细胞培养系统及纤维化肝细胞癌患者来源的MDSC中进行。
- 评估抗PD-L1单药或联合BET溴结构域抑制剂i-BET762(已进入临床试验)的疗效。
主要发现
- 在两种小鼠模型中,纤维化肝内单核细胞样MDSC(M-MDSC)而非多形核MDSC的积累与肿瘤浸润淋巴细胞减少及肿瘤生长增强显著相关。
- 在人肝细胞癌中,肿瘤周围纤维化肝组织显著富集M-MDSC,其替代标志物CD33与侵袭性肿瘤表型和较差生存率显著相关。
- 活化的肝星状细胞诱导单核细胞内在p38 MAPK信号,触发增强子重编程以促进M-MDSC发育和免疫抑制。
- p38 MAPK抑制剂可阻断肝星状细胞与M-MDSC的交互作用,从而阻止肝细胞癌生长。
- i-BET762抑制患者来源的M-MDSC,与抗PD-L1联合治疗协同增强肿瘤浸润淋巴细胞,导致纤维化肝细胞癌小鼠模型肿瘤根除和生存期延长。
关键数值与推荐
- M-MDSC的替代标志物CD33与侵袭性肿瘤表型和较差生存率显著相关。
- p38 MAPK抑制剂可阻断肝星状细胞-M-MDSC交互作用,阻止肝细胞癌生长。
临床怎么用
- 作者认为,靶向单核细胞内在的增强子重编程(如i-BET762联合抗PD-L1)可能为肝细胞癌免疫治疗提供可转化的联合策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hepatocellular carcinoma (HCC), mostly developed in fibrotic/cirrhotic liver, exhibits relatively low responsiveness to immune checkpoint blockade (ICB) therapy. As myeloid-derived suppressor cell (MDSC) is pivotal for immunosuppression, we investigated its role and regulation in the fibrotic microenvironment with an aim of developing mechanism-based combination immunotherapy. DESIGN: Functional significance of MDSCs was evaluated by flow cytometry using two orthotopic HCC models in fibrotic liver setting via carbon tetrachloride or high-fat high-carbohydrate diet and verified by clinical specimens. Mechanistic studies were conducted in human hepatic stellate cell (HSC)-peripheral blood mononuclear cell culture systems and fibrotic-HCC patient-derived MDSCs. The efficacy of single or combined therapy with anti-programmed death-1-ligand-1 (anti-PD-L1) and a clinically trialled BET bromodomain inhibitor i-BET762 was determined. RESULTS: Accumulation of monocytic MDSCs (M-MDSCs), but not polymorphonuclear MDSCs, in fibrotic livers significantly correlated with reduced tumour-infiltrating lymphocytes (TILs) and increased tumorigenicity in both mouse models. In human HCCs, the tumour-surrounding fibrotic livers were markedly enriched with M-MDSC, with its surrogate marker CD33 significantly associated with aggressive tumour phenotypes and poor survival rates. Mechanistically, activated HSCs induced monocyte-intrinsic p38 MAPK signalling to trigger enhancer reprogramming for M-MDSC development and immunosuppression. Treatment with p38 MAPK inhibitor abrogated HSC-M-MDSC crosstalk to prevent HCC growth. Concomitant with patient-derived M-MDSC suppression by i-BET762, combined treatment with anti-PD-L1 synergistically enhanced TILs, resulting in tumour eradication and prolonged survival in the fibrotic-HCC mouse model. CONCLUSION: Our results signify how non-tumour-intrinsic properties in the desmoplastic microenvironment can be exploited to reinstate immunosurveillance, providing readily translatable combination strategies to empower HCC immunotherapy.
引用
- Liu M, Zhou J, Liu X, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019. PMID: 31076403. doi:10.1136/gutjnl-2018-317257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。